Clinical Efficacy and Long-term Outcomes of ALLOgraft Versus Stented Biological Prosthesis for Primary TRIcuspid Valve Disease (ALLOTRI)
Recruiting
Observational Study
Allograft
Bioprosthesis
Tricuspid Valve Disease
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 – 70
- Sex
- Any
- Study type
- Observational
- Participants needed
- 56 (estimated)
- Sponsor
- Chelyabinsk Regional Clinical Hospital · Government
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The aim of the study is to evaluate early safety, clinical efficacy and long-term outcomes of mitral allografts and stented biological prosthesis in tricuspid valve replacement for primary tricuspid valve diseases.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Patients with primary tricuspid valve disease and/or tricuspid bioprosthetic failure scheduled for tricuspid valve intervention.
* Intraoperative findings suggested for tricuspid valve replacement rather than repair.
Exclusion Criteria:
* Pregnancy
* Confirmed active d…
Contacts